Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Differente Patterns of Telomerase Reverse Transcriptase (hTERT) mRNA Variant Expression Profiles in Patients with Myelodysplastic Syndromes (MDS) and Acute Myelogenous Leukemia (AML)

Evgenia Verrou, MD, Vassiliki Kaloutsi, MD, Phd, Eirini Katodritou, MD, Phd, Vasilia Garypidou, MD, Phd, Anna Nikitidou, Vassiliki Gastari, MD, Anna Lazaridou, MD, Phd, Konstantinos Zervas, MD, Phd, Vassiliki Kotoula, MD, Phd

Blood (2008) 112 (11): 4483.

https://doi.org/10.1182/blood.V112.11.4483.4483

Published: 2008

Journal Articles

Response to Bortezomib Therapy for Multiple Myeloma (MM) in Actual Clinical Practice: Preliminary Effectiveness Findings of an International Observational Study.

Michel Delforge, MD, PhD, Eirini Katodritou, MD, PhD, Konstantinos Zervas, MD, PhD, Deniz Sargin, MD, Cyrille Hulin, MD, Mats Linderholm, MD, PhD, Evgenia Verrou, MD, Vicki Poon, MPH, Ravinder Dhawan, PhD

Blood (2007) 110 (11): 4837.

https://doi.org/10.1182/blood.V110.11.4837.4837

Published: 2007

Journal Articles

Thalidomide–Containing Regimens Induce Recovery of Normal Immunoglobulins in Newly Diagnosed Patients with Multiple Myeloma; Recovery of Normal Immunoglobulins Improves Survival.

Eirini Katodritou, MD, PhD, Evgenia Verrou, MD, Anastasia Banti, MD, Dimitra Mihou, MD, Vassiliki Gastari, MD, Christina Hadjiaggelidou, MD, Dimitra Markala, MD, Anna Lazaridou, MD, PhD, Evangelos Terpos, MD, PhD, Konstantinos Zervas, MD, PhD

Blood (2007) 110 (11): 2738.

https://doi.org/10.1182/blood.V110.11.2738.2738

Published: 2007

Journal Articles

The International Prognostic Scoring System for Waldestrom’s Macroglobulinemia (ISSWM) Is Applicable in Patients Treated with Rituximab-Based Regimens.

Meletios Athanasios Dimopoulos, MD, Efstathios Kastritis, MD, Dimitra Gika, Sossana Delimpassi, MD, Konstantinos Zervas, MD, Argiris Simeonidis, MD, Evangelos Eleftherakis-Papaiakovou, MD, Nicolaos Anagnostopoulos, MD, Evridiki Michali, MD, Marie Christine Kyrtsonis, MD, Evangelos Terpos, MD, Gerassimos Pangalis, MD

Blood (2007) 110 (11): 3615.

https://doi.org/10.1182/blood.V110.11.3615.3615

Published: 2007

Journal Articles

The Addition of Thalidomide in Any Line of Treatment of Multiple Myeloma, Improves Overall Survival: Single Center Experience in 246 Patients.

Eirini Katodritou, MD, PhD, Evgenia Verrou, MD, Anastasia Banti, MD, Vassiliki Gastari, MD, Dimitra Mihou, MD, Christina Hadjiaggelidou, MD, Dimitra Markala, MD, Anna Lazaridou, MD, PhD, Evangelos Terpos, MD, PhD, Konstantinos Zervas, MD, PhD

Blood (2007) 110 (11): 4813.

https://doi.org/10.1182/blood.V110.11.4813.4813

Published: 2007

Journal Articles

Clinical Characteristics and Outcome of Primary AL Amyloidosis in Greece.

Michalis Michail, MD, Efstathios Kastritis, MD, Sossana Delimpassi, MD, Marie Christine Kyrtsonis, MD, Evridiki Michali, MD, Nicolaos Anagnostopoulos, MD, Konstantinos Zervas, MD, Eirini Katodritou, MD, Panagiotis Panagiotidis, MD, Natalia Tzenou, Gerassimos Pangalis, MD, Meletios Athanasios Dimopoulos, MD

Blood (2007) 110 (11): 4729.

https://doi.org/10.1182/blood.V110.11.4729.4729

Published: 2007

Journal Articles

Recombinant Human Erythropoietin May Negatively Influence Survival in Newly Diagnosed Patients with Multiple Myeloma: A Single Center Experience in 246 Patients.

Blood (2007) 110 (11): 4814.

https://doi.org/10.1182/blood.V110.11.4814.4814

Published: 2007

Journal Articles

Symptomatic Waldenstrom’s Macroglobulinemia (WM) in Young Patients: Disease Characteristics and Outcome.

Efstathios Kastritis, MD, Evangelos Eleftherakis-Papaiakovou, MD, Magdalini Migkou, MD, Dimitra Gika, Evangelos Terpos, MD, Konstantinos Zervas, MD, Marie Christine Kyrtsonis, MD, Nicolaos Anagnostopoulos, MD, Sossana Delimpassi, MD, Argiris Symeonidis, MD, Meletios Athanasios Dimopoulos, MD

Blood (2007) 110 (11): 4730.

https://doi.org/10.1182/blood.V110.11.4730.4730

Published: 2007

Journal Articles

VAD-doxil vs.VAD-doxil Plus Thalidomide as Initial Treatment in Patients with Multiple Myeloma: A Multicenter Randomized Trial of the Greek Myeloma Study Group.

Konstantinos Zervas, MD, Dimitra Mihou, M.D., Irini Katodritou, M.D., Anastasia Pouli, M.D., Chrisanthi H. Mitsouli, M.D., Athanasios Anagnostopoulos, M.D., Souzana Delimbasi, M.D., Marie-Christine Kyrtsonis, M.D., Nikolaos Anagnostopoulos, M.D., Evangelos Terpos, M.D., Panagiotis Zikos, M.D., Meletios A. Dimopoulos, M.D.

Blood (2006) 108 (11): 794.

https://doi.org/10.1182/blood.V108.11.794.794

Published: 2006

Journal Articles

Predictive Factors for Response and Progression after Treatment with Rituximab in Previously Untreated Patients with Waldenstrom’s Macroglobulinemia (WM).

Athanasios Anagnostopoulos, MD, Steven P. Treon, MD, Konstantinos Zervas, MD, Andrew Branagan, MD, Dimitra Gika, Athanasios Zomas, MD, Marie Christine Kyrtsonis, MD, Amalia Vassou, MD, Nikolaos Anagnostopoulos, MD, Gerasimos Pangalis, MD, Meletios A. Dimopoulos, MD

Blood (2005) 106 (11): 3485.

https://doi.org/10.1182/blood.V106.11.3485.3485

Published: 2005

Journal Articles

Prognostic Value of Serum β2-Microglobulin in Patients with Waldenstrom’s Macroglobulinemia Requiring Treatment.

Athanasios Anagnostopoulos, MD, Konstantinos Zervas, MD, Evangelos Terpos, MD, Marie Christine Kyrtsonis, MD, Argyris Symeonidis, MD, Dimitra Gika, Konstantinos Bourantas, MD, Athanasios Zomas, MD, Nikolaos Angnostopoulos, MD, Gerasimos Pangalis, MD, Meletios A. Dimopoulos, MD

Blood (2005) 106 (11): 3415.

https://doi.org/10.1182/blood.V106.11.3415.3415

Published: 2005

Journal Articles

Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma ≥ 75 Years of Age.

Meletios A. Dimopoulos, MD, Panagiotis Repoussis, MD, Evangelos Terpos, MD, Maria Christina Kyrtsonis, MD, Athanasios Zomas, MD, Eirini Katodritou, MD, Souzana Delibasi, MD, Amalia Vassou, MD, Athanasios Anagnostopoulos, MD, Anastasia Pouli, MD, Konstantinos Zervas, MD, Dimitrios Margaritis, MD, Nikolaos Anagnostopoulos, MD, Alice G. Maniatis, MD

Blood (2004) 104 (11): 1482.

https://doi.org/10.1182/blood.V104.11.1482.1482

Published: 2004

Journal Articles

Symptomatic Multiple Myeloma in Young Adults ≤ 40 Years of Age.

Argiris Symeonidis, MD, Anastasia Pouli, MD, Panagiotis Repoussis, MD, Konstantinos Zervas, MD, Athanasios Anagnostopoulos, MD, Chrysanthi Mitsouli, MD, Dimitra Gika, Alice Maniatis, MD, Meletios Athanasios Dimopoulos, MD

Blood (2004) 104 (11): 4906.

https://doi.org/10.1182/blood.V104.11.4906.4906

Published: 2004

Journal Articles

Prognostic Factors and Outcome of Older Patients with Symptomatic Multiple Myeloma: A Study of the Greek Myeloma Study Group (GMSG).

Athanasios Anagnostopoulos, MD, Dimitra Gika, Argiris Symeonidis, MD, Konstantinos Zervas, MD, Anastasia Pouli, MD, Panagiotis Repoussis, MD, Vassiliki Grigoraki, MD, Nikolaos Anagnostopoulos, MD, Alice G. Maniatis, MD, Meletios Athanasios Dimopoulos, MD

Blood (2004) 104 (11): 4847.

https://doi.org/10.1182/blood.V104.11.4847.4847

Published: 2004

NARROW

Differente Patterns of Telomerase Reverse Transcriptase (hTERT) mRNA Variant Expression Profiles in Patients with Myelodysplastic Syndromes (MDS) and Acute Myelogenous Leukemia (AML)

Response to Bortezomib Therapy for Multiple Myeloma (MM) in Actual Clinical Practice: Preliminary Effectiveness Findings of an International Observational Study.

Thalidomide–Containing Regimens Induce Recovery of Normal Immunoglobulins in Newly Diagnosed Patients with Multiple Myeloma; Recovery of Normal Immunoglobulins Improves Survival.

The International Prognostic Scoring System for Waldestrom’s Macroglobulinemia (ISSWM) Is Applicable in Patients Treated with Rituximab-Based Regimens.

The Addition of Thalidomide in Any Line of Treatment of Multiple Myeloma, Improves Overall Survival: Single Center Experience in 246 Patients.

Clinical Characteristics and Outcome of Primary AL Amyloidosis in Greece.

Recombinant Human Erythropoietin May Negatively Influence Survival in Newly Diagnosed Patients with Multiple Myeloma: A Single Center Experience in 246 Patients.

Symptomatic Waldenstrom’s Macroglobulinemia (WM) in Young Patients: Disease Characteristics and Outcome.

VAD-doxil vs.VAD-doxil Plus Thalidomide as Initial Treatment in Patients with Multiple Myeloma: A Multicenter Randomized Trial of the Greek Myeloma Study Group.

Predictive Factors for Response and Progression after Treatment with Rituximab in Previously Untreated Patients with Waldenstrom’s Macroglobulinemia (WM).

Prognostic Value of Serum β2-Microglobulin in Patients with Waldenstrom’s Macroglobulinemia Requiring Treatment.

Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma ≥ 75 Years of Age.

Symptomatic Multiple Myeloma in Young Adults ≤ 40 Years of Age.

Prognostic Factors and Outcome of Older Patients with Symptomatic Multiple Myeloma: A Study of the Greek Myeloma Study Group (GMSG).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only